Peptifact

GHK-Cu Results: What Was Measured in People, What Was Not, and the 55.8% Figure Explained

Every human result on record for GHK-Cu (copper peptide), read on 17 November 2026: the 8-week split-face serum trial (wrinkle volume −24.1% vs −15.0% for the vehicle), the 1994 diabetic-ulcer gel trial, the 1992 venous-ulcer trial in which a 0.4% copper-peptide cream did no better than placebo, three cream studies known only from conference abstracts, and zero published trials of injected GHK-Cu.

Robert F · Edited by Caroline S · Published 2026-11-17

Illustration: An open insulated shipping box showing cool blue gel packs and an empty clear glass vial within foam.
Illustration

"GHK-Cu results" means two different things online. One is a small set of human studies of copper peptide put on skin or into wounds, some positive, some not. The other is a large body of claims about copper peptide injected under the skin, for which no human trial has been published. This page lists every human measurement we could open on 17 November 2026, explains the figures most often quoted from them, and says where the record stops. Nothing here is a recommendation.

What GHK-Cu is — the tripeptide glycine-histidine-lysine bound to copper, present in blood plasma at about 200 ng/mL at age 20 and about 80 ng/mL by 60, according to the reviews cited below — is on Peptide Lexicon's GHK-Cu entry. The figures clinic and vendor pages state for dosing are on our GHK-Cu dosage page. Cosmetic use, serums and the skin reactions people call "copper uglies" are covered in depth by PeptideGlowJournal's copper peptides guide and its copper uglies page.

The short answer

Question What the record holds
Wrinkles, peer-reviewed trial 8 weeks, 40 women: wrinkle volume −24.1% with GHK-Cu serum vs −15.0% with the serum base (20-woman arm)
Wrinkles, other cream studies 12-week results in 71, 41 and 67 women — conference presentations, no full paper found
Diabetic foot ulcers 1994 gel trial: median 98.5% closure vs 60.8% with vehicle
Venous leg ulcers 1992 trial, 86 patients: 0.4% cream no better than placebo
After laser resurfacing 2006 trial, 13 patients: no objective difference; patients rated it higher
Hair Combination products only; the largest study had no control group
Injected GHK-Cu No published human trial

Every human result we could open

A PubMed search on 17 November 2026 for GHK-Cu and its chemical names, limited to human studies, returned 64 records. None was tagged as a clinical trial. Reading them, and following the reviews' references, gives this list of studies that measured something in people:

Study Who and how many What was applied Result
Badenhorst et al. 2016, J Aging Sci (DOI) 40 women aged 40–65, randomised, double-blind, one product per side of the face GHK-Cu in a lipid nano-carrier serum, twice daily, 8 weeks Wrinkle volume −24.1% vs −15.0% for the serum base; −25.8% vs −20.0% against a Matrixyl 3000 product
Mulder et al. 1994, Wound Repair Regen (PMID 17147644) People with diabetic neuropathic foot ulcers, multicentre, randomised, placebo-controlled GHK-Cu gel (Iamin) daily, with standard wound care Median closure of plantar ulcers 98.5% vs 60.8%; infection 7% vs 34% when started right after debridement
Bishop et al. 1992, J Vasc Surg (PMID 1495150) 86 evaluable patients with venous stasis ulcers, randomised, evaluator-blinded 0.4% tripeptide-copper cream vs silver sulfadiazine vs placebo Copper cream no better than placebo; silver sulfadiazine reduced ulcer size more than both
Miller et al. 2006, Arch Facial Plast Surg (PMID 16847171) 13 patients after CO2 laser resurfacing around the mouth, randomised Skin-care regimen with or without GHK-Cu, 12 weeks No difference in redness or wrinkles by blinded evaluators or software; patient-rated skin quality better with GHK-Cu (P = .04)
Byun et al. 2016, J Cosmet Laser Ther (PMID 27064823) One man aged 59 A five-ingredient solution including copper-GHK, sprayed in with a device, weekly for 12 weeks Fewer crow's-feet wrinkles in photographs; more collagen in a biopsy. A single case
Kapoor and Shome 2018, J Cosmet Laser Ther (PMID 29482481) 1,000 patients with hair loss, open-label, no control group Scalp injections of six growth factors and peptides, one of them copper tripeptide-1, every 3 weeks × 8 Less hair fall on pull test in 83%; hair count up at 1 year. GHK-Cu's share cannot be separated

Three cream studies are cited far more often than any of these: a 12-week facial cream in 71 women, a 12-week eye cream in 41 women that "performed better than placebo and vitamin K cream", and a 12-week facial study in 67 women aged 50 to 59, plus a thigh-skin study in which collagen production rose in 70% of women using GHK-Cu against 50% with vitamin C and 40% with retinoic acid. We could open their summaries in two reviews (Pickart and Margolina 2018; Pickart et al. 2015) but not the studies themselves: the references point to American Academy of Dermatology meeting presentations from February 2002, a 2005 book chapter and a 1998 pilot study. Both reviews list their authors at the R&D department of Skin Biology in Bellevue, Washington, and declare no conflict of interest. We report these figures as the reviews state them; none has the detail — controls, dropouts, concentration — that a published trial would give.

The 55.8% figure, and what the trial actually measured

The Badenhorst trial is the source of "GHK-Cu reduced wrinkle volume by 55.8%", which recurs on clinic and vendor pages. The paper's own tables show what that number is:

Arm (20 women each) Side of face Wrinkle volume change at 8 weeks Wrinkle depth change at 8 weeks
Group 2 GHK-Cu serum −24.1% −20.3%
Group 2 Serum base without GHK-Cu −15.0% −15.3%
Group 1 GHK-Cu serum −25.8% −26.8%
Group 1 Matrixyl 3000 product −20.0% −22.4%

The 55.8% is the statistical model's estimate of the relative improvement of the GHK-Cu side over the base-only side — not a fall of 55.8% from where the wrinkles started. On the raw averages, wrinkles shrank on both sides of the face, and the serum base alone accounted for most of the change. The GHK-Cu side's extra was about nine percentage points over 8 weeks.

The paper also states the limits a reader needs: the women were 40 to 65 with no further skin criteria reported in the abstract; one product went on each side of each face, so the comparison is within-person; one woman of 40 stopped after a reaction on both sides; and the study was funded by Snowberry New Zealand, the company whose serum was tested, which the authors say had no role in the analysis. The concentration of GHK-Cu in the serum is not stated.

What injected GHK-Cu has behind it

Nothing published in people. On 17 November 2026:

  • PubMed returned no human study of GHK-Cu by subcutaneous, intramuscular or intravenous injection. The one injected product with copper tripeptide-1 in it (Kapoor 2018, above) was a six-ingredient scalp mix with no control group.
  • ClinicalTrials.gov listed four studies mentioning GHK-Cu: a recruiting 60-person phase 2 trial of a 0.1% topical gel on standardised skin wounds (NCT07437586, Hudson Biotech); a 48-person "aging clock" study using a topical peptide serum (NCT07888595); a patch study measuring blood GHK levels, not yet recruiting (NCT07706361, LifeWave); and a completed facial-treatment study (NCT05932732). None tests injection; none has posted results.
  • FDA lists GHK-Cu for injectable routes among the peptides nominated for compounding and then withdrawn from consideration (see our Category 2 list page). It has no approval for any use.
  • A 2026 review in Sports Medicine lists GHK-Cu among unapproved peptides marketed direct to patients and concludes that rigorous human safety data for such compounds "are scarce" (Mendias and Awan, PMID 41966639).

The case made for injection on clinic pages rests on reasoning — cream reaches the skin, injection reaches the blood — and on animal studies of wounds, lungs and muscle. Those are reasons to run a trial, not results of one.

The timelines online, against the record

Claim, as published Where, and when we read it What the record says
"Weeks one to four": little beyond improved hydration; changes build "over several months" up to month six Belle Health blog, updated 20 October 2026 The one peer-reviewed trial measured differences at 4 and 8 weeks; nothing in people beyond 12 weeks for skin
"4–8 weeks for skin, 8–12 weeks for hair" A phrase repeated across several pages in the 17 November 2026 search results for "ghk cu results", none citing a study No hair trial of GHK-Cu alone; skin figures as above
A double-blind trial showing skin density +17% and fine lines −35% at 12 weeks Healthspan, published 21 September 2026 We could not match these figures to any study in PubMed or in the two reviews above
Copper peptide "comparable or superior" to minoxidil for hair loss, citing a 2019 Annals of Dermatology paper Healthspan, same page The DOI the page lists resolves to a 2019 paper on diabetes in burn patients; PubMed held no copper-peptide-versus-minoxidil trial under that citation on 17 November 2026

Reports on Reddit and in social video describe results within the first week. A first-week change in how skin looks or feels is consistent with what the serum base did in the 2016 trial, which improved wrinkles with no GHK-Cu in it.

What these results do not tell anyone

  • Whether injected GHK-Cu does anything in people. No trial has measured it.
  • How a 2026 serum compares with the products tested. Concentrations were mostly unstated, the nano-carrier in the 2016 trial was specific to that serum, and the 2002 cream formulations are not described in any source we could open.
  • Long-term effects. No study we found ran past 12 weeks on skin or a year on the scalp.
  • Side effects on injection. The adverse events recorded with topical use and reported by people injecting are on our peptide side effects page.

Whether any copper-peptide product suits a particular person is a question for a dermatologist or prescriber. For how other peptides' human records look when laid out the same way, see our MOTS-c results and CJC-1295 results pages.

Sources

  • PubMed E-utilities: GHK-Cu, copper tripeptide, glycyl-histidyl-lysine and prezatide in title or abstract, limited to humans (64 records), and the same terms with clinical-trial publication types (0 records); searched 17 November 2026.
  • Badenhorst T, Svirskis D, Merrilees M, Bolke L, Wu Z. Effects of GHK-Cu on MMP and TIMP expression, collagen and elastin production, and facial wrinkle parameters. J Aging Sci 2016;4:166, doi:10.4172/2329-8847.1000166 — full text, Tables 2 and 3 and Disclosure, opened 17 November 2026.
  • Mulder GD et al. Wound Repair Regen 1994;2:259–69 (PMID 17147644); Bishop JB et al. J Vasc Surg 1992;16:251–7 (PMID 1495150); Miller TR et al. Arch Facial Plast Surg 2006;8:252–9 (PMID 16847171); Byun SY et al. J Cosmet Laser Ther 2016;18:293–5 (PMID 27064823); Kapoor R, Shome D. J Cosmet Laser Ther 2018;20:369–79 (PMID 29482481) — abstracts read 17 November 2026.
  • Pickart L, Margolina A. Int J Mol Sci 2018;19:1987 (PMC6073405) and Pickart L, Vasquez-Soltero JM, Margolina A. Biomed Res Int 2015:648108 (PMC4508379) — full texts, section on cosmetic use, affiliations and conflict statements, read 17 November 2026.
  • Joerg L, Zafar K, Jagdeo J. Peptides for hair growth: a systematic review. J Drugs Dermatol 2026;25:1026–32 (PMID 42976838); Mendias CL, Awan TM. Sports Med 2026;56:1921–35 (PMID 41966639) — abstracts read 17 November 2026.
  • ClinicalTrials.gov API v2, query GHK-Cu, copper peptide, copper tripeptide, prezatide (4 studies), records NCT07437586, NCT07888595, NCT07706361, NCT05932732, read 17 November 2026.
  • Belle Health, "GHK-Cu before and after" and "GHK-Cu reviews" (updated 20 October 2026); Healthspan, "GHK-Cu injection vs topical" (published 21 September 2026), and Crossref record for doi:10.5021/ad.2019.31.1.51 — read 17 November 2026.

Frequently asked questions

How long does GHK-Cu take to work?

On the skin, the peer-reviewed trial measured a difference at 4 and 8 weeks, and the conference-reported cream studies ran 12 weeks. Clinic and vendor pages state 4 to 8 weeks for skin and 8 to 12 for hair, but cite no study for those timelines. For injected GHK-Cu there is no timeline to report: no human trial of injection has been published.

Does injected GHK-Cu work?

Unknown. PubMed held no published human trial of GHK-Cu by injection on 17 November 2026, and the registry listed none. Every controlled human result on record is for a cream, serum or gel applied to skin or a wound. Reports of injected results come from clinic marketing pages, forums and social video, which cannot separate the compound from everything else a person changes.

What does the 55.8% GHK-Cu wrinkle result mean?

It comes from the 2016 Badenhorst trial and is the statistical model's estimate of how much better the GHK-Cu side of the face did than the side given the serum base without GHK-Cu. The raw averages were a 24.1% fall in wrinkle volume with GHK-Cu and a 15.0% fall with the base alone over 8 weeks, in 20 women. The base itself improved wrinkles.

Has GHK-Cu ever failed a trial?

Yes. In a 1992 trial of 86 patients with venous leg ulcers, a 0.4% tripeptide-copper cream did no better than placebo at shrinking ulcers, while silver sulfadiazine did. In a small 2006 trial after CO2 laser resurfacing, blinded evaluators found no difference in redness or wrinkles, though patients using GHK-Cu products rated their skin quality higher.

Does GHK-Cu help hair growth?

The human record is thin and mixed with other ingredients. A 2026 systematic review graded formulations containing glycyl-histidyl-lysine peptide at level B, based on combination products. The largest scalp study, 1,000 patients injected with a mix of six growth factors and peptides including copper tripeptide-1, had no control group, so the GHK-Cu share of any effect cannot be measured.